Egetis Therapeutics AB (publ) Total Liabilities
Egetis Therapeutics AB (publ) total liabilities. Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has total liabilities worth Skr288.70 Million SEK (≈ $31.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Egetis Therapeutics AB (publ) fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Egetis Therapeutics AB (publ) (2008–2025)
Total liabilities of Egetis Therapeutics AB (publ) from 2008 to 2025. This chart illustrates how Egetis Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.
Egetis Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qualipoly Chemical Corp
TW:4722
|
Taiwan | NT$3.60 Billion |
|
Sinosun Tech
SHE:300333
|
China | CN¥13.94 Million |
|
Zaptec AS
OL:ZAP
|
Norway | Nkr425.90 Million |
|
Nagarro SE
XETRA:NA9
|
Germany | €587.94 Million |
|
Fujian Rongji Software Co Ltd
SHE:002474
|
China | CN¥1.16 Billion |
|
HeNan Splendor Science & Technology Co Ltd
SHE:002296
|
China | CN¥802.43 Million |
|
Pony Testing International Group Co
SHE:300887
|
China | CN¥513.12 Million |
|
Martinrea International Inc.
TO:MRE
|
Canada | CA$2.39 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Egetis Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EGTX total assets.
Liquidity & Leverage Metrics
Egetis Therapeutics AB (publ) Total Liabilities Ratios Explained
Egetis Therapeutics AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Egetis Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Egetis Therapeutics AB (publ) (2008–2025)
The table below shows the annual total liabilities of Egetis Therapeutics AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr300.40 Million ≈ $32.33 Million |
+0.33% |
| 2024-12-31 | Skr299.40 Million ≈ $32.22 Million |
+39.52% |
| 2023-12-31 | Skr214.60 Million ≈ $23.09 Million |
+290.89% |
| 2022-12-31 | Skr54.90 Million ≈ $5.91 Million |
+30.00% |
| 2021-12-31 | Skr42.23 Million ≈ $4.54 Million |
-84.02% |
| 2020-12-31 | Skr264.34 Million ≈ $28.45 Million |
+949.09% |
| 2019-12-31 | Skr25.20 Million ≈ $2.71 Million |
+11.12% |
| 2018-12-31 | Skr22.68 Million ≈ $2.44 Million |
+94.52% |
| 2017-12-31 | Skr11.66 Million ≈ $1.25 Million |
+69.61% |
| 2016-12-31 | Skr6.87 Million ≈ $739.64K |
+58.77% |
| 2015-12-31 | Skr4.33 Million ≈ $465.87K |
-66.21% |
| 2014-12-31 | Skr12.81 Million ≈ $1.38 Million |
+215.75% |
| 2013-12-31 | Skr4.06 Million ≈ $436.60K |
-37.74% |
| 2012-12-31 | Skr6.52 Million ≈ $701.23K |
+67.36% |
| 2011-12-31 | Skr3.89 Million ≈ $418.98K |
+159.12% |
| 2010-12-31 | Skr1.50 Million ≈ $161.69K |
+448.39% |
| 2009-12-31 | Skr273.98K ≈ $29.48K |
-15.32% |
| 2008-12-31 | Skr323.55K ≈ $34.82K |
-- |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for… Read more